Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis in susceptible bacteria.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Treatment of serious infections caused by susceptible gram-negative bacteria,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burns,Off-label: Bacterial endocarditis prophylaxis,Off-label: Intraocular injection for endophthalmitis
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
1-2 mg/kg IV every 8 hours, adjusted based on serum concentrations and creatinine clearance.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Terminal elimination half-life: 2-3 hours in adults with normal renal function; prolonged to 24-48 hours in anuric patients requiring dose adjustment.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Gentamicin is not significantly metabolized; it is excreted primarily unchanged by glomerular filtration.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal: >90% unchanged via glomerular filtration; biliary: <2%; fecal: negligible.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
<30% bound primarily to albumin; low binding reduces displacement interactions.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
0.2-0.3 L/kg; approximates extracellular fluid volume; increased in edema, ascites, or burns.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Intramuscular: ~100%; topical: minimal systemic absorption (<1%); intravenous: 100% (by definition).
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
Cr Cl 60-90 m L/min: 1.7 mg/kg every 12 hours; Cr Cl 40-59 m L/min: 1.7 mg/kg every 24 hours; Cr Cl 20-39 m L/min: 1.7 mg/kg as a single dose then adjust based on serum levels; Cr Cl <20 m L/min: 1.7 mg/kg as a single dose then redose based on serum levels; Hemodialysis: 1-2 mg/kg after dialysis with supplemental dosing based on serum levels.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No dose adjustment required for hepatic impairment; gentamicin is primarily renally eliminated.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Neonates (<7 days): 4-5 mg/kg IV every 24-36 hours; Infants >7 days: 2.5 mg/kg IV every 8 hours; Children: 2-2.5 mg/kg IV every 8 hours; adjust based on serum concentrations and renal function.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Dose adjustment based on renal function; calculate Cr Cl using Cockcroft-Gault equation with ideal body weight; typical starting dose: 1-1.7 mg/kg IV every 8-12 hours, with subsequent dosing guided by serum concentrations.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
WARNING: OTOTOXICITY AND NEPHROTOXICITY. Gentamicin can cause ototoxicity (vestibular and auditory) and nephrotoxicity. Risk increases with prolonged use, high doses, renal impairment, and advanced age. Monitor renal function and auditory function regularly.
None.
Neurotoxicity including ototoxicity and nephrotoxicity,Neuromuscular blockade leading to respiratory paralysis,Superinfection with resistant organisms,May worsen weakness in myasthenia gravis or Parkinson's disease,Use with caution in premature infants and neonates due to renal immaturity,Monitor serum drug levels to avoid toxicity
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hypersensitivity to gentamicin or other aminoglycosides,Severe renal disease with anuria (relative contraindication; use only if benefits outweigh risks)
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No significant food interactions. Avoid excessive potassium intake if renal impairment.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Gentamicin is classified as FDA Pregnancy Category D. There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk. First trimester: Avoid unless essential due to potential for ototoxicity and nephrotoxicity. Second and third trimesters: Use only for severe infections when alternative antibiotics are not available. Risk of fetal inner ear damage and renal impairment associated with aminoglycosides.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Gentamicin is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.15-0.2. Oral bioavailability in infants is poor, minimizing systemic absorption. However, potential for disruption of infant gut flora and direct irritation. Use with caution, especially in neonates with immature renal function. Monitor infant for diarrhea or rash.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Increased volume of distribution and enhanced renal clearance during pregnancy may necessitate higher doses or more frequent administration to achieve therapeutic serum levels. Therapeutic drug monitoring is recommended. Initial dosing based on ideal body weight and renal function; adjust to maintain target peak (6-10 mcg/m L) and trough (<2 mcg/m L) concentrations.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Monitor peak (30 min after 30-min infusion) and trough (just before next dose) levels; target peak 5-10 mcg/m L, trough <2 mcg/m L. Adjust dose in renal impairment. Avoid concurrent ototoxic/nephrotoxic drugs. Consider once-daily dosing for synergy with beta-lactams. Assess for vestibular toxicity with Romberg test.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Report any hearing loss, ringing in ears, dizziness, or balance problems immediately.,Drink plenty of fluids unless instructed otherwise by your doctor.,Inform your doctor if you have kidney disease, myasthenia gravis, or are pregnant.,This medication is given intravenously; do not mix with other drugs in the same line without pharmacy approval.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Gentamicin, an aminoglycoside antibiotic, and Amphotericin B, a polyene antifungal agent, both independently induce nephrotoxicity. Concurrent administration synergistically increases the risk of acute kidney injury, characterized by elevated serum creatinine, reduced glomerular filtration rate, and potential tubular necrosis. This additive nephrotoxic effect necessitates cautious use and enhanced monitoring."
"Pamidronic acid, a bisphosphonate, inhibits osteoclast-mediated bone resorption, reducing serum calcium levels. Gentamicin, an aminoglycoside antibiotic, can cause renal tubular injury, impairing the kidney's ability to reabsorb calcium and leading to hypocalcemia. Concurrent use increases the risk of severe, symptomatic hypocalcemia, potentially manifesting as tetany, arrhythmias, or seizures."
"Gentamicin and foscarnet both have nephrotoxic potential, and concurrent use can lead to additive or synergistic renal injury. This interaction increases the risk of acute kidney injury, particularly in patients with pre-existing renal impairment or volume depletion, and may result in reduced glomerular filtration rate and elevated serum creatinine."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis in susceptible bacteria.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 1-2 mg/kg IV every 8 hours, adjusted based on serum concentrations and creatinine clearance.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Gentamicin is classified as FDA Pregnancy Category D. There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.